

Monthly DRUP newsletter 67, 01 October 2021

Dear all,

To date, a total of 1830 cases have been submitted to the study team and more than 900 patients have started on one of the 31 study treatments. Also for the 3rd stage Nivolumab cohort the inclusion is going very well. This cohort was extended to the third stage exactly two years ago and is already with its 124 enrolled patient almost full.

Information for participating sites

For all participating sites we would like to use this opportunity to draw attention to the following; a baseline scan cannot be more than 28 days old before start treatment. If this is the case we would kindly ask you to repeat this scan. Thank you in advance for your understanding.

Next to this we would also like to inform you that the crizotinib cohort for MET mutation NSCLC is currently put on hold. This cohort is almost full and the last slots are currently reserved for potential patients.

Update new website

The website keeps improving and this month's new feature is an interactive map showing all the participating DRUP sites and where they are located around the country. The goal of this map is to make it easier for both potential patients and the treating team to know where to find us. Furthermore, only for participating sites, a list of available drugs and cohorts is to be found after logging in to the protected area. With our to date 221 different cohorts this list is very extensive. A tip; use the 'f' search function to easier find a cohort for a specific indication/gene mutation.

Events & meetings



On 27th of September our semi-annual pharma meeting took place in the AVL. We were very excited to again be able to arrange this on location and to see everyone live after such a long time. There was a great attendance and the DRUP team look back at a very successful meeting.

Best regards,

Henk Verheul, Hans Gelderblom and Emile Voest, principle Investigators
Maxime van Berge Henegouwen, Laurien Zeverijn, Gijs de Wit and Birgit Geurts, study coordinators
Lena Bilet, trial manager

List of pharmaceutical companies & study drugs			
Confidential, list might be subjected to change			
Currently available			
<u>Amgen</u>	<u>Eisai</u>	<u>Bayer</u>	<u>Roche</u>
Panitumumab	Lenvatinib	Regorafenib	Erlotinib
			Trastuzumab +
<u>BMS</u>	<u>AstraZeneca</u>	<u>Clovis Oncology</u>	Pertuzumab
Nivolumab	Olaparib	Rucaparib	Vemurafenib +
Ipilimumab	Durvalumab		Cobimetinib
		<u>MSD</u>	Vismodegib
<u>Novartis</u>	<u>Pfizer</u>	Pembrolizumab	Atezolizumab +
Dabrafenib	Axitinib		bevacizumab
Nilotinib	Crizotinib	<u>Lilly</u>	Alectinib
Trametinib	Sunitinib	Abemaciclib	Entrectinib
Ribociclib	Palbociclib		
Alpelisib	Talazoparib,	<u>BI</u>	
	dacomitinib	Afatinib	
	Lorlatinib		
Committed			
<u>Janssen</u>			
Erdafitinib			

Calendar & publicity
NOVEMBER
Submission protocol amendment 15: adding of new study compounds



Participating sites			
Currently open for inclusion (n = 35)			
<ul style="list-style-type: none"> AMC AVL Amphia Bravis Deventer Ziekenhuis Erasmus MC ETZ Franciscus Gelderse Vallei Gelre Ziekenhuizen 	<ul style="list-style-type: none"> Haaglanden MC Haga ziekenhuis Isala Martini Maxima MC MC Leeuwarden Meander Nij Smellinghe Treant Zorggroep NWZ 	<ul style="list-style-type: none"> Reinier de Graaf Rijnstate Spaarne Gasthuis St. Antonius UMC Groningen UMC Leiden Maastricht UMC Radboud UMC UMC Utrecht VieCuri 	<ul style="list-style-type: none"> ZG Twente Zuyderland Rivas Zorggroep OLVG VUMC <p>In preparation (n=2)</p> <ul style="list-style-type: none"> Maasstad Bernhoven

DRUGS OPEN FOR INCLUSION			
Nilotinib	KIT _{mut} GIST	PDGFRA _{mut} GIST	PDGFRA _{mut} mesothelioma
	PDGFRB _{amp} CRC	KIT _{mut} melanoma	KIT _{mut} kiemcel tumor
Nivolumab	MSI tumors	HML tumors	3 rd stage MSI tumors
Nivolumab + ipilimumab	HML tumors		
Olaparib	ATM _{mut} tumors	BRCA _{mut} tumors	HRR deficient tumors (2x)
Panitumumab	RAF/RAS _{wt} sarcoma	RAF/RAS _{wt} HNSCC	EGFR _{mut} NSCLC
	RAF/RAS _{wt} thyroid ca	RAF/RAS _{wt} salivary duct ca	RAF/RAS _{wt} cervical ca
	RAF/RAS _{wt} endometrial ca	RAF/RAS _{wt} meningioma	RAF/RAS _{wt} eye melanoma
	RAF/RAS _{wt} GBM	RAF/RAS _{wt} vulvar ca	RAF/RAS _{wt} ACUP
	RAF/RAS _{wt} anal ca		
Pembrolizumab	HML CRC	HML eso/card/stomach	HML HNSCC
	HML prostate ca	HML breast ca	HML miscellaneous
	HML > 290 (all type)		
Regorafenib	RET+ NSCLC	RET+ neuroblastoma	KIT _{mut} melanoma
	KIT _{mut} Thymuscarcinoma	BRAF _{mut} ACC	FLT1 _{amp} duodenal carcinoma
Dabraf + Tramet	BRAF _{mut} NSCLC	BRAF _{mut} GBM	BRAF _{mut} low grade glioma
	BRAF _{mut} NEC	BRAF _{mut} cholangiocarcinoom	BRAFV600E _{mut} breast cancer
	BRAFV600E _{mut} grade 3 glioma		
Dabrafenib	BRAF _{mut} GBM	BRAF _{mut} UCC	
Trametinib	NRAS _{mut} ovarian ca	MAP2K1 _{mut} NSCLC	NRAS _{mut} NSCLC
	MAP3K1 _{mut} NEC	MAP3K1 _{mut} cervical ca	MAP2K1 _{mut} CRC
	MAP2K4 _{mut} CRC	MAP3K1 _{mut} ACUP	MAP2K4 _{mut} cholangioca
	MAP2K4 _{mut} ovarian ca	MAP3K1 _{mut} breast ca	MAP2K4 _{mut} breast ca
	NRAS _{mut} thyroid cancer	MAP3K1 _{mut} prostate	NRAS _{mut} pleomorphic tumor
	NRAS _{mut} prostate	BRAF _{fusie} (pilocytair) astrocytoom	NRAS _{mut} yolk sac tumor
	GNA11 _{mut} melanocytair tumor	NRAS _{mut} cholangio cancer	BRAF _{exon 12} deletion NSCLC
	BRAF _{fusie} NSCLC	NRAS _{mut} salivary duct ca	MAP2K4 _{loss} pancreas cancer
	NF1 _{mut} low grade glioma	BRAF _{fusie} pancreas cancer	MAP2K1 _{mut} pancreas cancer
	MAP2K1 _{mut} stomach cancer		
Trastuz. + Pertuz.	HER2 _{amp} CRC	HER2 _{amp} cholangio ca	HER2 _{mut} NSCLC
	HER2 _{mut} ovarian ca	HER2 _{amp} salivary duct ca	HER2 _{amp} NSCLC
	HER2 _{mut} CRC	HER2 _{mut} cervical ca	HER2 _{amp} vulvar ca
	HER2 _{amp} cervical ca	HER2 _{amp} hidradenoca	HER2 _{amp} UCC
	HER2 _{amp} ovarian ca	HER2 _{amp} NEC	HER2 _{mut} UCC
	HER2 _{mut} ACC	HER2 _{amp} duodenal cancer	
Vemur. + Cobimet.	BRAF _{mut} salivary duct	BRAF _{mut} ACUP	BRAF _{mut} ovarian ca
	BRAF _{mut} thyroid ca	BRAF _{non-V600mut} NSCLC	BRAF _{V600Emut} Erdheim Chester Disease
Vismodegib	PTCH1 _{mut} Sarcoma	PTCH1 _{mut} medulloblastoma	
Erlotinib	EGFR _{mut} GBM	CRC with EGFR mutations	EGFR fusions GBM
Lenvatinib	FGFR1 _{amp} CRC	FGFR2 _{amp} CRC	FGFR2 _{amp} breast ca
	FGFR1 _{amp} Osteosarcoma	FGFR1 _{amp} NSCLC	FGFR3 _{mut} anal ca
	FGFR2 _{amp} esophageal ca	FGFR2 _{mut} endometrial ca	FGFR3 _{amp} SGT
	FGFR2 _{fusie} ACUP	FGFR2 _{fusie} cholangioca	FGFR1 _{amp} breast ca
	FGFR2 _{amp} Urachal ca	FGFR3 _{mut} UCC	FGFR2 _{mut} ACC
	FGFR3 _{amp} NEC nasal cavity	FGFR1 _{mut} glioneural tumor	FGFR3 _{mut} HNSCC
	FGFR3 _{fusie} GBM	FGFR2 _{mut} digital papillary cancer	FGFR2 _{fusion} pancreas cancer
	FGFR2 _{amp} NSCLC	FGFR3 _{fusie} cholangioca	FGFR2 _{mut} cholangioca/biliary tract
	FGFR1 _{amp} pancreas cancer	FGFR2 _{mut} salivary duct cancer	
Sunitinib	KIT _{mut} thymus ca	PDGFRA _{mut} prostate ca	FGFR1 _{amp} UCC
	PDGFRB _{amp} breast ca	PDGFRB _{mut} osteosarcoma	PDGFRA _{amp} ACC
	FGFR1 _{amp} Ovarian cancer	PDGFRA _{amp} tyroid cancer	FTL3 _{amp} CRC
	CSF1R _{mut} CRC	KIT _{amp} NSCLC	FGFR2 _{amp} ovarian cancer
Crizotinib	ALK _{fus} IMT	MET _{amp} CRC	ALK _{mut} CRC
	MET _{mut} NSCLC	MET _{amp} esophageal ca	MET _{amp} NSCLC
	ALK _{mut} thyroid	ALK _{fus} leiomyosarcoma	ALK _{fusion} CUP
	MET _{fusion} anaplastic tyroid cancer	MET _{amp} HCC	MET _{amp} GEJ-tumor
	MET _{amp} Ovarium cancer	MET _{mut} (papillair) kidney cell cancer	
Axitinib	FLT1 _{amp} CRC		
Rucaparib	HRR _{alt} ovarian cancer	HRR _{alt} prostate cancer	HRR _{alt} pancreatic cancer
	HRR _{alt} miscellaneous	HRR _{alt} Breast cancer	
Alectinib	ALK fusion (all tumor types)		
Abemaciclib	CCND1 _{amp} UCC	CCND1 _{amp} NSCLC	CCND1 _{amp} prostate cancer
	CCND1 _{amp} melanoma	CCND3 _{amp} small intestine	CDK4 _{amp} (lipo)sarcomen
Alpelisib	Miscellaneous tumors with PIK3CA _{mut}	PIK3CA _{mut} SCC gynecologic tumors	PIK3CA _{mut} gynecologic tumors
	PIK3CA _{mut} upper-GI tumors	PIK3CA _{mut} HNSCC	PTEN _{loss} prostate cancer
Talazoparib	Tumors with HRD signature		
Legend	Cohort closed	Cohort on hold	Slots available

DRUGS CLOSED FOR INCLUSION			
Palbociclib	CDKN2A _{loss} GBM	CDKN2A _{loss} CRC	CDKN2A _{loss} PEComa
	SMARCA4 _{mut} ovarian ca	CDKN2A _{mut} cholangio ca	CDKN2A _{mut} melanoma
	CDKN2A _{loss} duodenal ca	CCND1 _{ampl} NSCLC	CDKN2A _{loss} RCC
	CDKN2A _{loss} HNSCC	CDKN2A _{del} esophageal ca	CCND1 _{ampl} melanoma
	CDKN2A _{mut} uveal melanoma	CDK4 _{ampl} Sarcoma	CCND1 _{ampl} NET
	CDKN2A _{loss} pancreatic ca	CDKN2A _{loss} vulvar ca	CDK4 _{ampl} astrocytoma
	CDKN2A _{del} NSCLC	CDK4 _{ampl} prostate cancer	CDK4 _{ampl} esophageal cancer
	CDKN2A _{loss} pNET	CDKN2A _{loss} ovarian cancer	CCND2 _{ampl} CRC
CDK6 _{ampl} prostate cancer	SMARCA4 _{mut} CRC		
Durvalumab	MSI tumors		
Cabozantinib	MET _{ampl} melanoma	RET _{fusion} NSCLC	MET _{ampl} teratoma
	NTRK2 _{mut} GIST	MET _{mut} oesofagus cancer	
Ribociclib	CDKN2A _{loss} prostate cancer	CDKN2A _{loss} ependymoma	CDK4 _{ampl} melanoma
	CDKN2A _{del} anaplastic meningioma	CDKN2A _{loss} thymus carcinoma	CDKN2A _{loss} Ewing Sarcoma
	CDKN21 _{del/mut} bladder cancer	CDK6 _{amp} mucoepidermoid cancer	CDKN2A _{del} mesothelioma
	CDKN2A _{loss} ceruminous cancer	CDKN2A _{del} salivary gland cancer	
Afatinib	NRG1 _{fusie} NSCLC	NRG1 _{fusie} breast ca	NRG1 _{fusie} GI tumors
	NRG1 _{fusie} miscellaneous (all tumors)	HER4 _{mut} NSCLC	
Legend	Cohort closed	Cohort on hold	Slots available